Chronic Disease Drugmakers

The thesis

Established prescription-drug franchises offer exposure to recurring treatment demand rather than AI infrastructure spending. Lilly's reimbursement debate puts the focus on whether patient growth can offset pricing pressure, while the basket diversifies across metabolic, inflammatory, cardiovascular and other chronic diseases. Recent strength makes valuation and pipeline execution important risks rather than reasons to assume further gains.